All In Biotech

Investigational drug · Phase 3

Pembolizumab

Also called: pembro

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Gastric Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M).

Phase 3

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

9

Any phase or sponsor naming "Pembolizumab"

First trial start

2025

Jun 15, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Pembolizumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HER2-positive Gastric Cancer
  • Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Approved drugs for the same conditions: Stomach and esophageal cancer · Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Pembolizumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 103 on PubMed

Also in development for HER2-positive Gastric Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • JSKN003Phase 37 trials

    Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer

  • KN026PlacboPhase 37 trials

    Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer

  • HLX22Phase 34 trials

    Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.